Biogen stock rallies after full-day halt as FDA panel recommends Alzheimer's drug for approval
Biogen Inc. (BIIB) shares rallied in the extended session late Friday following a full-day halt after the biotech company received a recommendation from a Food and Drug Administration advisory committee to approve an Alzheimer's treatment it makes with
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
June 09, 2023 19:28 ET (23:28 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.